ElectroCore will initially release its handheld gammaCore vagus-nerve stimulation device, which was cleared by the FDA in April to treat cluster headaches, to about 50 of the 160 US headache centers in the middle of this month, said company CEO Frank Amato. The company is conducting trials to assess use of the external handheld device in treating migraines and is also looking into the device's potential as a treatment for other conditions, such as neurological disorders, rheumatoid arthritis, nonalcoholic steatohepatitis and nonalcoholic fatty-liver disease.
ElectroCore eyes gammaCore's initial US release this month
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.